Johnson & Johnson maintained a solid gross margin despite the Synthes acquisition and negative currency impacts, with operational sales growth aligning with expectations. However, their reaffirmed earnings guidance, combined with uncertainties such as the ongoing remediation of McNeil's OTC business and market fluctuations, are likely to lead to a neutral short-term stock price reaction.
[0]